Overview of Progressive Nature of CKD. Describe the need for screening and diagnosis in T2D patients. Describe the role of SGLT2 inhibitors as initial therapy in patients with T2D and CKD. Overview of DAPA-CKD trial outcomes and primary endpoints.
For further medical information requests and access to other AstraZeneca resources, please go to www.azmedical.com or please contact AstraZeneca at 1-877-893-1510. Please refer to the Farxiga Prescribing Information for further product information.
Disclaimer: This content was created by AstraZeneca healthcare professionals for use by healthcare professionals. AstraZeneca is committed to conducting business with the highest standards of integrity and professionalism.